InflammationNCT03176212
Effect of Milk Fat Globule Membrane (MFGM) on Gut Barrier Protection in Runners
A study testing Milk fat globule membrane in people with Inflammation, run by Utah State University.
Trial summary
This study was designed to determine if an ingredient in milk fat can prevent gut leakiness induced by running at 80% maximum oxygen consumption (VO2max). In mouse studies, the milk fat ingredient, and individual components thereof, have been shown to reduce gut leakiness induced by intra peritoneal lipopolysaccharide… Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Inflammation
- What is being tested?
- Milk fat globule membrane
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14 participants
- Where
- No sites listed yet
- Study dates
- Jan 2012to Jan 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Ability to run at 80%V02max for 30m, availability to complete the study.
Who cannot join
- Heart disease, uncontrolled hypertension, diabetes, Crohn's Disease, irritable bowel syndrome, colitis, celiac disease, inflammatory or autoimmune diseases, and lactose intolerance.
About this study
This study was designed to determine if an ingredient in milk fat can prevent gut leakiness induced by running at 80% maximum oxygen consumption (VO2max). In mouse studies, the milk fat ingredient, and individual components thereof, have been shown to reduce gut leakiness induced by intra peritoneal lipopolysaccharide (LPS) injections.
The investigators hypothesis is as follows: Compared to a sports drink with identical macro nutrient composition, a sports drink with milk fat globule membrane (MFGM) will reduce the change in gut leakiness induced by running at 90% VO2max for 30 minutes. The decrease in gut permeability change will be associated with a decreased area under the curve of plasma endotoxin for 5 hours following the exercise. In addition, decreased gut permeability will be associated with lower area under the curve values for inflammatory cytokines.
Read the detailed description
A randomized, double-blind cross-over exercise trial was conducted with 14 runners on Utah State University campus. This population of 14 runners was selected from a larger population of 20 that was recruited to complete two initial trials. In two preliminary visits, the parameters necessary for conducting the experimental trial were determined. During the first visit, a baseline value was determined for gut permeability as well as aerobic capacity of runners. In the second visit the capacity to complete a run at 80% VO2max was tested and the effect of the exercise stress on gut permeability, plasma LPS and core temperature were measured.
Once a test population was selected, a randomized, double-blind, cross-over trial was conducted in which MFGM was tested for the ability to prevent a change in the exercise induced gut permeability.
During each testing session heart rate (HR), work output and core temperature (CT) were monitored. HR and CT were monitored by a CorTemp™ temperature pill which was ingested by the athletes prior to the trial (http://www.hqinc.net/pages/pill_page.html). In addition, blood was drawn at baseline (before depletion trial), immediately after the time trial, and again at 1h and 5h. Blood was analyzed for indices of training intensity (lactate), muscle damage (creatine kinase, cytokines), and gut barrier dysfunction (lipopolysaccharide, cytokines). In addition, immediately after the run athletes consumed a beverage with two carbohydrates (lactulose, and rhamnose). During the following six hours urine was collected and these sugars were measured via gas chromatography to determine the permeability of the gut.
Subject Recruitment Twenty, runners (ages 18-50) were initially recruited via campus flyers, advertisements in the local paper and weekly sports guide. Participants who had medical histories including: heart disease, uncontrolled hypertension, diabetes, Crohn's Disease, irritable bowel syndrome, colitis, Celiac disease, inflammatory or autoimmune diseases or lactose intolerance were excluded from the study. All subjects were instructed to avoid all anti-inflammatory medications for at least 24 h prior to any testing activity. On the morning of the first visit, approved subjects had body composition measured by BodPod (Life Measurement, Inc., Concord, CA). Participants were asked to refrain from any heavy exercise for 48 hrs before the first visit. Subjects were given a 50 ml tube containing the 5 g lactulose and 2 g rhamnose sugar probe and instructed to drink the probe 4hrs after they have finished breakfast to determine baseline gut permeability. Subjects were given a urine collection container and instructed to collect all urine for 6 hrs after ingestion of the probe. Subjects were not to eat lunch until 1.5 hrs after drinking the sugar probe. After 6 hrs of urine collection, subjects returned to the test site and performed a running VO2 max test.
Second Visit (approximately one week after first visit) Approximately 3 hrs after completion of breakfast, subjects reported to the test site to have blood drawn (to determine baseline plasma LPS), weight measured and to ingest a temperature probe. Participants started the exercise challenge (60 minute run at 80% VO2 max) approximately 4 hrs after completion of breakfast. The exercise challenge was conducted in a climate-controlled room at 22 °C without a fan. Subjects were monitored to ensure they were running at 80% VO2 max and were not allowed to consume water during the challenge. Immediately after the exercise challenge, participants consumed the sugar probes. Weight was measured, blood drawn (post-exercise plasma LPS) and subjects were instructed to collect their urine for the next six hrs. To facilitate re hydration and urine production, subjects were instructed to replace 150% of their fluid losses (pre to post exercise weight) by water intake.
After screening 20 subjects, a population of fifteen subjects agreed to participate in the cross-over trial. One subject dropped out due to a pregnancy, and four subjects could participate due to scheduling conflicts. One subject dropped out after sustaining a broken ankle that was not related to the study.
The third and fourth visits were the crossover portion of the experiment comparing MFGM to the vehicle. The 3rd and 4th visits were identical to the 2nd visit except participants drank either the fluid replacement vehicle or fluid replacement + MFGM 1 hr before the exercise challenge and again immediately following the exercise. Participants and personnel administering experimental protocols were blinded to treatments by use of coded, non-transparent drink containers. Subjects complete the 4th visit one week later and consume the vehicle beverage or the vehicle + MFGM.
For the crossover portion of the study, athletes were provided one of two beverages. The control beverage was formulated according to current sports nutrition guidelines for both pre- and post-workout nutrient delivery. It contained whey protein, sucrose, maltodextrins, chocolate flavoring and a small amount of butter oil. The test beverage was identical on a macro nutrient content, but contained a milk based ingredient called 'milk fat globule membrane.' This material is isolated from a byproduct of butter production, and is rich in phospholipids. The beverages were provided three hours prior to the exercise trial as well as immediately after. The test beverage contained a powder rich in MFGM that is produced by Arla Foods (Lacprodan PL-20) which contains roughly 20% phospholipids and 60% protein. In studies with mice, Dial et al have noted effects on gut protection in 1 h when animals are provided with phospholipids at 100mg/kg body weight. The second beverage was matched for macronutrient content, but did not contain the phospholipid powder.
Endpoints measured Change in gut Permeability To determine resting, baseline intestinal permeability the method of Pals was used. This method determines intestinal permeability by supplying the non-digestable sugars lactulose, and rhamnose and estimates intestinal and gastric permeability by recovery of these sugar probes in the urine. In healthy gut epithelia, lactulose has very limited transport across the gut barrier. Rhamnose crosses the small intestinal epithelia via a transcellular route and serves as internal control to account for gastric emptying rate, intestinal transit time and renal function. The larger lactulose molecule can only cross gut epithelia via a paracellular route through tight junctions. Therefore a higher ratio of lactulose to rhamnose recovered in the urine indicates compromised intestinal barrier function. Exercise stress has been demonstrated to significantly increase the urinary lactulose/rhamnose ratio . Similar to our proposed exercise stress model, this method has been used to demonstrate that running at 80% VO2max for an hour doubles gut permeability compared to baseline.
Change in plasma LPS: To assess endotoxemia, plasma LPS concentrations were measured via a kinetic activity as described by Nieman. Plasma LPS was measured from blood taken before exercise (baseline), immediately following, and at 1 and 5 hours after the exercise trial. Plasma LPS has been demonstrated to increase after endurance exercise bouts and is hypothesized to be the result of aberrant bacterial translocation of gut bacteria through compromised gut barrier. Elevated plasma LPS from baseline immediately after exercise has been demonstrated previously after a half-marathon, full marathon. It was anticipated that plasma LPS levels would increase after exercise stress and will be correlated to core body temperature and the lactulose/rhamnose index of gut barrier integrity.
Change in inflammatory Cytokines: Plasma levels of IL-6, TNFα, IL-10, IL-17, INFγ, IL-3, MCP-1, IL-15 and GMCSF were measured in the baseline and in the 1 h post exercise samples. Cytokine concentrations were determined by multiplex enzyme-linked immunosorbent assay (ELISA) by a commercial vendor (Quansys Biosystems, Logan, UT). These cytokines were selected based on a previous study investigating gut leakiness and MFGM consumption in an LPS-stimulated gut leakiness trial with mice. All cytokines were significantly upregulated in animals with leaky guts except GMCSF, and were significantly lowered in MFGM-fed animals compared to controls. Moreover, Ng et al demonstrated increased plasma levels of IL-10 and IL-6 (50% and 65.2% increase from baseline respectively) in runners immediately following a half marathon. Similarly, plasma levels of IL-6 and TNFα have been demonstrated to be increased from baseline immediately after a marathon. Based on the preliminary data and the aforementioned studies, it was anticipated that increased levels of inflammatory cytokines would be measured after the exercise challenge and it was hypothesized MFGM would abrogate this effect compared to the other recovery beverages.
Change in plasma creatine kinase: Creatine kinase was measured in samples taken before, immediately after and 1 hours after the exercise challenge. Creatine kinase was measured by using a commercial colorimetric kit (Sigma) in a 96-well UV/vis plate reader (Molecular Devices). Increased plasma creatine kinase is a well-established index of exercise induced muscle damage. In a similar study, cyclists riding at 85% VO2 max until exhaustion after glycogen depletion the previous day had less plasma creatine kinase when they consumed chocolate milk as a recovery drink compared to a carbohydrate replacement beverage.
Plasma Lactate: To assess anaerobic metabolism, plasma lactate will be measured at baseline, immediately after and 2 hours subsequent the exercise stress. Lactate will be measured using an enzymatic test kit (r-Biopharm, Marshall, MI).
The primary endpoint measured in this study was the lactulose/rhamnose ratios in urine and plasma LPS. The data were analyzed by single factor ANOVA and significant differences were explored with post-hoc testing. Core body temperature was measured in real time and was correlated with gut hypoxia and with gut leakiness.
All components measured in the blood (lactate, LPS, cytokines, and CK) were analyzed by a two factor ANOVA with time and treatment as variables. Lactate was included as it is generally considered to be an index of anaerobic activity. One other parameter were interested in is creatine kinase. As mentioned in the introduction, this enzyme is detected in the blood after intense exercise and is thought to correlate with damage to muscles. Furthermore, at least two studies with chocolate milk have noted that plasma CK is lower in athletes drinking chocolate milk vs. other recovery drinks.
Management plan All three PIs were actively involved in the planning and execution of this study, as well as in the sample processing and the analysis. Dr. Ward was responsible for formulation of the MFGM beverage. In addition, Dr. Ward was responsible for the GC-FID analysis of the urine. In addition, Dr. Ward will supervised a graduate student supported by this project.
Dr. Bressel recruited the athletes and helped with organizing the tests. In addition, Dr. Bressel supervised all of the performance trials and the collection of the exercise data.
Dr. Hintze was in charge of the blood and urine samples. The student (and perhaps Dr. Hintze) conducted the LPS the lactate and the CK assays. In addition, Dr. Hintze was responsible for proper sample handing of the blood and for the specimen delivery to Quansys Biosystems for the cytokine analysis.
All three PIs collaborated on the data analysis and on manuscript preparation.
- Conditions
- Inflammation
- Being tested
- Milk fat globule membrane
- Keywords
- Gut permeability, Cytokine, Endotoxin
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Milk fat globule membraneDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Beverage with milk fat globule membrane | Active comparator | In this arm, subjects consumed a beverage Receives: Dietary Supplement: Milk fat globule membrane |
| Control | Placebo comparator | In this arm, subjects consumed a beverage with identical macronutrients Receives: Dietary Supplement: Milk fat globule membrane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in gut permeability via differential sugar test
In this outcome, the barrier properties of the gut are assessed indirectly. Subjects consume a mixture of lactulose and mannitol. Mannitol is a monosaccharide and is passively absorbed from the gut and eliminated via the urine. Lactulose, on the other hand, is an indigestible disaccharide. If it appears in the urine, it is thought to pass into the body through loose tight junctions between the mouth and large intestine. If it reaches the large intestine, lactulose will be fermented by the microbiome.
Subjects consume the sugar mixture and urine is collected for 6 hours. In this study, gut permeability was measured at baseline, and after after the running tests.
Measured: Gut permeability was measured three times in this study. Once at baseline, and twice after the exercise challenges. The total time to complete the assessment was approximately 3 weeks.
Secondary outcomes (5)
Core temperature increase
Higher core temperatures are associated with increased gut permeability. Two of our primary measures were gut permeability assessments by the differential sugar test and plasma LPS. The increase in core temperature was included to give context to those measures. Prior to the exercise test, subjects consumed a thermometer pill and core temperature was monitored with a recording device.
Measured: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma lactate
Plasma lactate was measured as an index of exercise intensity. It was measured before the exercise challenge, and immediately after. It was also measured at 1 hour and 4 hours post exercise.
Measured: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma cytokines
To determine the systemic inflammatory response, plasma cytokines were measured before the exercise test and at 1h and 5h later. Plasma cytokines were measured with a multiplexed ELISA kit.
Measured: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma endotoxin
Higher levels of plasma endotoxin (aka LPS) are thought to occur due to a leaky gut
Measured: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma creatine kinase
Creatine kinase was measured as an index of muscle stress. It was measured before the exercise challenge, and immediately after. It was also measured at 1 hour and 4 hours post exercise.
Measured: This outcome was measured twice in a time frame of less than three weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2017
- Study startJan 2012
- Primary completionJan 2013
- Study completionJan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Utah State University
- Sponsor type
- University, hospital or other
- Collaborators
- Dairy Research Institute
- Responsible party
- Principal investigator, Robert Ward, Utah State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03176212
- Sponsor's protocol ID
- 101082
- Status last verified
- May 2017
- First submitted
- 10 May 2017
- Last updated
- 5 Jun 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Dial EJ, Zayat M, Lopez-Storey M, Tran D, Lichtenberger L. Oral phosphatidylcholine preserves the gastrointestinal mucosal barrier during LPS-induced inflammation. Shock. 2008 Dec;30(6):729-33. doi: 10.1097/SHK.0b013e318173e8d4.
PubMed 18496240Pals KL, Chang RT, Ryan AJ, Gisolfi CV. Effect of running intensity on intestinal permeability. J Appl Physiol (1985). 1997 Feb;82(2):571-6. doi: 10.1152/jappl.1997.82.2.571.
PubMed 9049739Davis MS, Willard MD, Williamson KK, Steiner JM, Williams DA. Sustained strenuous exercise increases intestinal permeability in racing Alaskan sled dogs. J Vet Intern Med. 2005 Jan-Feb;19(1):34-9. doi: 10.1892/0891-6640(2005)192.0.co;2.
PubMed 15715045Lambert GP. Intestinal barrier dysfunction, endotoxemia, and gastrointestinal symptoms: the 'canary in the coal mine' during exercise-heat stress? Med Sport Sci. 2008;53:61-73. doi: 10.1159/000151550.
PubMed 19208999Smetanka RD, Lambert GP, Murray R, Eddy D, Horn M, Gisolfi CV. Intestinal permeability in runners in the 1996 Chicago marathon. Int J Sport Nutr. 1999 Dec;9(4):426-33. doi: 10.1123/ijsn.9.4.426.
PubMed 10660873Nieman DC, Henson DA, Dumke CL, Oley K, McAnulty SR, Davis JM, Murphy EA, Utter AC, Lind RH, McAnulty LS, Morrow JD. Ibuprofen use, endotoxemia, inflammation, and plasma cytokines during ultramarathon competition. Brain Behav Immun. 2006 Nov;20(6):578-84. doi: 10.1016/j.bbi.2006.02.001. Epub 2006 Mar 22.
PubMed 16554145Lambert GP, Lang J, Bull A, Pfeifer PC, Eckerson J, Moore G, Lanspa S, O'Brien J. Fluid restriction during running increases GI permeability. Int J Sports Med. 2008 Mar;29(3):194-8. doi: 10.1055/s-2007-965163. Epub 2007 Jul 5.
PubMed 17614027Ng QY, Lee KW, Byrne C, Ho TF, Lim CL. Plasma endotoxin and immune responses during a 21-km road race under a warm and humid environment. Ann Acad Med Singap. 2008 Apr;37(4):307-14.
PubMed 18461215Pritchett K, Bishop P, Pritchett R, Green M, Katica C. Acute effects of chocolate milk and a commercial recovery beverage on postexercise recovery indices and endurance cycling performance. Appl Physiol Nutr Metab. 2009 Dec;34(6):1017-22. doi: 10.1139/H09-104.
PubMed 20029509
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Milk Fat Globule Membrane (MFGM) on Gut Barrier Protection in Runners
- ClinicalTrials.gov ID
- NCT03176212
- Acronym / sponsor ID
- 101082
- Conditions
- Inflammation
- Keywords
- Gut permeability, Cytokine, Endotoxin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Utah State UniversityUniversity, hospital or other
- Collaborators
- Dairy Research Institute
- Study start
- Jan 2012
- Primary completion
- Jan 2013 (actual)
- Study completion
- Jan 2013 (actual)
- First posted
- 5 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was designed to determine if an ingredient in milk fat can prevent gut leakiness induced by running at 80% maximum oxygen consumption (VO2max). In mouse studies, the milk fat ingredient, and individual components thereof, have been shown to reduce gut leakiness induced by intra peritoneal lipopolysaccharide (LPS) injections.
The investigators hypothesis is as follows: Compared to a sports drink with identical macro nutrient composition, a sports drink with milk fat globule membrane (MFGM) will reduce the change in gut leakiness induced by running at 90% VO2max for 30 minutes. The decrease in gut permeability change will be associated with a decreased area under the curve of plasma endotoxin for 5 hours following the exercise. In addition, decreased gut permeability will be associated with lower area under the curve values for inflammatory cytokines.
Detailed description
A randomized, double-blind cross-over exercise trial was conducted with 14 runners on Utah State University campus. This population of 14 runners was selected from a larger population of 20 that was recruited to complete two initial trials. In two preliminary visits, the parameters necessary for conducting the experimental trial were determined. During the first visit, a baseline value was determined for gut permeability as well as aerobic capacity of runners. In the second visit the capacity to complete a run at 80% VO2max was tested and the effect of the exercise stress on gut permeability, plasma LPS and core temperature were measured.
Once a test population was selected, a randomized, double-blind, cross-over trial was conducted in which MFGM was tested for the ability to prevent a change in the exercise induced gut permeability.
During each testing session heart rate (HR), work output and core temperature (CT) were monitored. HR and CT were monitored by a CorTemp™ temperature pill which was ingested by the athletes prior to the trial (http://www.hqinc.net/pages/pill_page.html). In addition, blood was drawn at baseline (before depletion trial), immediately after the time trial, and again at 1h and 5h. Blood was analyzed for indices of training intensity (lactate), muscle damage (creatine kinase, cytokines), and gut barrier dysfunction (lipopolysaccharide, cytokines). In addition, immediately after the run athletes consumed a beverage with two carbohydrates (lactulose, and rhamnose). During the following six hours urine was collected and these sugars were measured via gas chromatography to determine the permeability of the gut.
Subject Recruitment Twenty, runners (ages 18-50) were initially recruited via campus flyers, advertisements in the local paper and weekly sports guide. Participants who had medical histories including: heart disease, uncontrolled hypertension, diabetes, Crohn's Disease, irritable bowel syndrome, colitis, Celiac disease, inflammatory or autoimmune diseases or lactose intolerance were excluded from the study. All subjects were instructed to avoid all anti-inflammatory medications for at least 24 h prior to any testing activity. On the morning of the first visit, approved subjects had body composition measured by BodPod (Life Measurement, Inc., Concord, CA). Participants were asked to refrain from any heavy exercise for 48 hrs before the first visit. Subjects were given a 50 ml tube containing the 5 g lactulose and 2 g rhamnose sugar probe and instructed to drink the probe 4hrs after they have finished breakfast to determine baseline gut permeability. Subjects were given a urine collection container and instructed to collect all urine for 6 hrs after ingestion of the probe. Subjects were not to eat lunch until 1.5 hrs after drinking the sugar probe. After 6 hrs of urine collection, subjects returned to the test site and performed a running VO2 max test.
Second Visit (approximately one week after first visit) Approximately 3 hrs after completion of breakfast, subjects reported to the test site to have blood drawn (to determine baseline plasma LPS), weight measured and to ingest a temperature probe. Participants started the exercise challenge (60 minute run at 80% VO2 max) approximately 4 hrs after completion of breakfast. The exercise challenge was conducted in a climate-controlled room at 22 °C without a fan. Subjects were monitored to ensure they were running at 80% VO2 max and were not allowed to consume water during the challenge. Immediately after the exercise challenge, participants consumed the sugar probes. Weight was measured, blood drawn (post-exercise plasma LPS) and subjects were instructed to collect their urine for the next six hrs. To facilitate re hydration and urine production, subjects were instructed to replace 150% of their fluid losses (pre to post exercise weight) by water intake.
After screening 20 subjects, a population of fifteen subjects agreed to participate in the cross-over trial. One subject dropped out due to a pregnancy, and four subjects could participate due to scheduling conflicts. One subject dropped out after sustaining a broken ankle that was not related to the study.
The third and fourth visits were the crossover portion of the experiment comparing MFGM to the vehicle. The 3rd and 4th visits were identical to the 2nd visit except participants drank either the fluid replacement vehicle or fluid replacement + MFGM 1 hr before the exercise challenge and again immediately following the exercise. Participants and personnel administering experimental protocols were blinded to treatments by use of coded, non-transparent drink containers. Subjects complete the 4th visit one week later and consume the vehicle beverage or the vehicle + MFGM.
For the crossover portion of the study, athletes were provided one of two beverages. The control beverage was formulated according to current sports nutrition guidelines for both pre- and post-workout nutrient delivery. It contained whey protein, sucrose, maltodextrins, chocolate flavoring and a small amount of butter oil. The test beverage was identical on a macro nutrient content, but contained a milk based ingredient called 'milk fat globule membrane.' This material is isolated from a byproduct of butter production, and is rich in phospholipids. The beverages were provided three hours prior to the exercise trial as well as immediately after. The test beverage contained a powder rich in MFGM that is produced by Arla Foods (Lacprodan PL-20) which contains roughly 20% phospholipids and 60% protein. In studies with mice, Dial et al have noted effects on gut protection in 1 h when animals are provided with phospholipids at 100mg/kg body weight. The second beverage was matched for macronutrient content, but did not contain the phospholipid powder.
Endpoints measured Change in gut Permeability To determine resting, baseline intestinal permeability the method of Pals was used. This method determines intestinal permeability by supplying the non-digestable sugars lactulose, and rhamnose and estimates intestinal and gastric permeability by recovery of these sugar probes in the urine. In healthy gut epithelia, lactulose has very limited transport across the gut barrier. Rhamnose crosses the small intestinal epithelia via a transcellular route and serves as internal control to account for gastric emptying rate, intestinal transit time and renal function. The larger lactulose molecule can only cross gut epithelia via a paracellular route through tight junctions. Therefore a higher ratio of lactulose to rhamnose recovered in the urine indicates compromised intestinal barrier function. Exercise stress has been demonstrated to significantly increase the urinary lactulose/rhamnose ratio . Similar to our proposed exercise stress model, this method has been used to demonstrate that running at 80% VO2max for an hour doubles gut permeability compared to baseline.
Change in plasma LPS: To assess endotoxemia, plasma LPS concentrations were measured via a kinetic activity as described by Nieman. Plasma LPS was measured from blood taken before exercise (baseline), immediately following, and at 1 and 5 hours after the exercise trial. Plasma LPS has been demonstrated to increase after endurance exercise bouts and is hypothesized to be the result of aberrant bacterial translocation of gut bacteria through compromised gut barrier. Elevated plasma LPS from baseline immediately after exercise has been demonstrated previously after a half-marathon, full marathon. It was anticipated that plasma LPS levels would increase after exercise stress and will be correlated to core body temperature and the lactulose/rhamnose index of gut barrier integrity.
Change in inflammatory Cytokines: Plasma levels of IL-6, TNFα, IL-10, IL-17, INFγ, IL-3, MCP-1, IL-15 and GMCSF were measured in the baseline and in the 1 h post exercise samples. Cytokine concentrations were determined by multiplex enzyme-linked immunosorbent assay (ELISA) by a commercial vendor (Quansys Biosystems, Logan, UT). These cytokines were selected based on a previous study investigating gut leakiness and MFGM consumption in an LPS-stimulated gut leakiness trial with mice. All cytokines were significantly upregulated in animals with leaky guts except GMCSF, and were significantly lowered in MFGM-fed animals compared to controls. Moreover, Ng et al demonstrated increased plasma levels of IL-10 and IL-6 (50% and 65.2% increase from baseline respectively) in runners immediately following a half marathon. Similarly, plasma levels of IL-6 and TNFα have been demonstrated to be increased from baseline immediately after a marathon. Based on the preliminary data and the aforementioned studies, it was anticipated that increased levels of inflammatory cytokines would be measured after the exercise challenge and it was hypothesized MFGM would abrogate this effect compared to the other recovery beverages.
Change in plasma creatine kinase: Creatine kinase was measured in samples taken before, immediately after and 1 hours after the exercise challenge. Creatine kinase was measured by using a commercial colorimetric kit (Sigma) in a 96-well UV/vis plate reader (Molecular Devices). Increased plasma creatine kinase is a well-established index of exercise induced muscle damage. In a similar study, cyclists riding at 85% VO2 max until exhaustion after glycogen depletion the previous day had less plasma creatine kinase when they consumed chocolate milk as a recovery drink compared to a carbohydrate replacement beverage.
Plasma Lactate: To assess anaerobic metabolism, plasma lactate will be measured at baseline, immediately after and 2 hours subsequent the exercise stress. Lactate will be measured using an enzymatic test kit (r-Biopharm, Marshall, MI).
The primary endpoint measured in this study was the lactulose/rhamnose ratios in urine and plasma LPS. The data were analyzed by single factor ANOVA and significant differences were explored with post-hoc testing. Core body temperature was measured in real time and was correlated with gut hypoxia and with gut leakiness.
All components measured in the blood (lactate, LPS, cytokines, and CK) were analyzed by a two factor ANOVA with time and treatment as variables. Lactate was included as it is generally considered to be an index of anaerobic activity. One other parameter were interested in is creatine kinase. As mentioned in the introduction, this enzyme is detected in the blood after intense exercise and is thought to correlate with damage to muscles. Furthermore, at least two studies with chocolate milk have noted that plasma CK is lower in athletes drinking chocolate milk vs. other recovery drinks.
Management plan All three PIs were actively involved in the planning and execution of this study, as well as in the sample processing and the analysis. Dr. Ward was responsible for formulation of the MFGM beverage. In addition, Dr. Ward was responsible for the GC-FID analysis of the urine. In addition, Dr. Ward will supervised a graduate student supported by this project.
Dr. Bressel recruited the athletes and helped with organizing the tests. In addition, Dr. Bressel supervised all of the performance trials and the collection of the exercise data.
Dr. Hintze was in charge of the blood and urine samples. The student (and perhaps Dr. Hintze) conducted the LPS the lactate and the CK assays. In addition, Dr. Hintze was responsible for proper sample handing of the blood and for the specimen delivery to Quansys Biosystems for the cytokine analysis.
All three PIs collaborated on the data analysis and on manuscript preparation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Beverage with milk fat globule membrane | Active comparator | Dietary Supplement: Milk fat globule membraneIn this arm, subjects consumed a beverage |
| Control | Placebo comparator | Dietary Supplement: Milk fat globule membraneIn this arm, subjects consumed a beverage with identical macronutrients |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Ability to run at 80%V02max for 30m, availability to complete the study.
Key exclusion criteria (1 listed)
- Heart disease, uncontrolled hypertension, diabetes, Crohn's Disease, irritable bowel syndrome, colitis, celiac disease, inflammatory or autoimmune diseases, and lactose intolerance.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Milk fat globule membrane | Dietary supplement | Beverage with milk fat globule membrane, Control |
Primary outcome
Change in gut permeability via differential sugar test
Time frame: Gut permeability was measured three times in this study. Once at baseline, and twice after the exercise challenges. The total time to complete the assessment was approximately 3 weeks.
In this outcome, the barrier properties of the gut are assessed indirectly. Subjects consume a mixture of lactulose and mannitol. Mannitol is a monosaccharide and is passively absorbed from the gut and eliminated via the urine. Lactulose, on the other hand, is an indigestible disaccharide. If it appears in the urine, it is thought to pass into the body through loose tight junctions between the mouth and large intestine. If it reaches the large intestine, lactulose will be fermented by the microbiome. Subjects consume the sugar mixture and urine is collected for 6 hours. In this study, gut permeability was measured at baseline, and after after the running tests.
5 secondary outcomes
Core temperature increase
Time frame: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma lactate
Time frame: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma cytokines
Time frame: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma endotoxin
Time frame: This outcome was measured twice in a time frame of less than three weeks.
Change in plasma creatine kinase
Time frame: This outcome was measured twice in a time frame of less than three weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2017.
- Background: PubMed 18496240Dial EJ, Zayat M, Lopez-Storey M, Tran D, Lichtenberger L. Oral phosphatidylcholine preserves the gastrointestinal mucosal barrier during LPS-induced inflammation. Shock. 2008 Dec;30(6):729-33. doi: 10.1097/SHK.0b013e318173e8d4.
- Background: PubMed 9049739Pals KL, Chang RT, Ryan AJ, Gisolfi CV. Effect of running intensity on intestinal permeability. J Appl Physiol (1985). 1997 Feb;82(2):571-6. doi: 10.1152/jappl.1997.82.2.571.
- Background: PubMed 15715045Davis MS, Willard MD, Williamson KK, Steiner JM, Williams DA. Sustained strenuous exercise increases intestinal permeability in racing Alaskan sled dogs. J Vet Intern Med. 2005 Jan-Feb;19(1):34-9. doi: 10.1892/0891-6640(2005)192.0.co;2.
- Background: PubMed 19208999Lambert GP. Intestinal barrier dysfunction, endotoxemia, and gastrointestinal symptoms: the 'canary in the coal mine' during exercise-heat stress? Med Sport Sci. 2008;53:61-73. doi: 10.1159/000151550.
- Background: PubMed 10660873Smetanka RD, Lambert GP, Murray R, Eddy D, Horn M, Gisolfi CV. Intestinal permeability in runners in the 1996 Chicago marathon. Int J Sport Nutr. 1999 Dec;9(4):426-33. doi: 10.1123/ijsn.9.4.426.
- Background: PubMed 16554145Nieman DC, Henson DA, Dumke CL, Oley K, McAnulty SR, Davis JM, Murphy EA, Utter AC, Lind RH, McAnulty LS, Morrow JD. Ibuprofen use, endotoxemia, inflammation, and plasma cytokines during ultramarathon competition. Brain Behav Immun. 2006 Nov;20(6):578-84. doi: 10.1016/j.bbi.2006.02.001. Epub 2006 Mar 22.
- Background: PubMed 17614027Lambert GP, Lang J, Bull A, Pfeifer PC, Eckerson J, Moore G, Lanspa S, O'Brien J. Fluid restriction during running increases GI permeability. Int J Sports Med. 2008 Mar;29(3):194-8. doi: 10.1055/s-2007-965163. Epub 2007 Jul 5.
- Background: PubMed 18461215Ng QY, Lee KW, Byrne C, Ho TF, Lim CL. Plasma endotoxin and immune responses during a 21-km road race under a warm and humid environment. Ann Acad Med Singap. 2008 Apr;37(4):307-14.
- Background: PubMed 20029509Pritchett K, Bishop P, Pritchett R, Green M, Katica C. Acute effects of chocolate milk and a commercial recovery beverage on postexercise recovery indices and endurance cycling performance. Appl Physiol Nutr Metab. 2009 Dec;34(6):1017-22. doi: 10.1139/H09-104.
- Individual participant dataSharing planned: No
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Milk fat globule membrane in people with Inflammation, run by Utah State University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in gut permeability via differential sugar test (time frame: Gut permeability was measured three times in this study. Once at baseline, and twice after the exercise challenges. The total time to complete the assessment was approximately 3 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03176212, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2017.